01 Oct Serum-backed IntegriMedical’s needle-free injection picks up pace
IntegriMedical has launched India’s first Needle-Free Injection System (N-FIS), gaining popularity among healthcare professionals for its pain-reducing benefits. With CDSCO approval and partnerships, the company aims to expand its market presence in India and Europe, addressing needle-related fears.
Are you scared of needles and dread going for a vaccine or shot? Whether it’s for your children or yourself, the fear is common!
The Needle-Free Injection System is gaining traction in the country.
According to IntegriMedical, a healthcare solutions company that claims to have developed India’s first Needle-Free Injection System (N-FIS), the increase in sales since its launch indicates that healthcare professionals are recommending or switching to needle-free systems to accommodate children and needle-phobic patients.
IntegriMedical received CDSCO approval for N-FIS in December 2022 and formally launched it in the retail market in April 2024, following initial piloting in 2023.
Sarvesh Mutha, MD of IntegriMedical, told CNBC-TV18 that since the launch, “sales have been substantially growing, with over 500 doctors administering more than 35,000 injections in India, along with initiating sales activities in Europe.”
He noted that “mostly, doctors in the private sector in metro, Tier 1, and Tier 2 cities across India have adopted this technology, with North and West leading the way. Typically, paediatricians are using N-FIS to vaccinate children over six months for intramuscular and subcutaneous injections, while some use it for children over three months.”
The company believes that as awareness increases, more Indians will opt for this system to make the injection experience less traumatic and painful.
To address the widespread fear of needles, particularly among children and those who are needle-phobic, IntegriMedical aims to eliminate the need for needles in medical treatments. The company claims that the solution has been clinically proven to reduce pain during administration.
“N-FIS has regulatory approvals in Europe and India through its CE mark and CDSCO approvals and is manufactured in an MDSAP and ISO 13485 compliant facility,” the company states.
Patented in the United States, the N-FIS device utilises a high-velocity jet stream powered by mechanical force to effectively and consistently administer biologics and drugs under the skin quickly without causing tissue damage.
IntegriMedical has also formed a strategic partnership with the world’s largest vaccine manufacturer, Serum Institute of India, which has acquired a 20% stake in the company to advance needle-free injection technology.
Looking to the future, Mutha says, “With increasing demand for patient-friendly, efficient, and safe drug delivery methods, the company is well-positioned to expand its market presence, particularly in India and Europe. Additionally, we are focused on expanding our regulatory approval portfolio to facilitate broader adoption in international markets.”